Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial [Corrigendum]

This article refers to:

Morning and evening efficacy evaluation of rupatadine (10 and 20 mg), compared with cetirizine 10 mg in perennial allergic rhinitis: a randomized, double-blind, placebo-controlled trial

Marmouz F, Giralt J, Izquierdo I. Journal of Asthma and Allergy. 2011;4:27–35.

On page 30, Table 1 was incorrect. The corrected table is shown below.

Table 1 Demographic and clinical characteristics at baseline in ITT population

Variable	Placebo	Rupatadine 10 mg	Rupatadine 20 mg	Cetirizine 10 mg
	(n=70)	(n=65)	(n=68)	(n=66)
Gender (male%)	27 (38)	18 (27)	26 (37)	28 (41)
Age (years)	30.9	31.4	33.8	32.2
Race (caucasian%)	69 (97)	65 (100)	68 (100)	63 (92)
5TSS mean value	8.80	8.75	8.10	8.39
4NTSS mean value	7.67	7.38	7.07	7.23

Notes: 5TSS: total symptoms score was calculated by adding the 5 symptom scores: rhinorrhea, sneezing, nasal itching, nasal obstruction, and conjunctival itching; 4NTSS: total nasal symptoms score was calculated by adding the 4 symptom scores: rhinorrhea, sneezing, nasal itching, and nasal obstruction. No significant differences were found between treatment groups.

On page 31, Tables 2 and 3 were incorrect. The corrected tables are shown below.

Table 2 Summary of morning (morning reflective) total symptoms score (5TSS) and nasal total symptoms score (4NTSS) assessments (ITT population)

		Placebo		Rupatadine 10 mg		Rupatadine 20 mg		Cetirizine 10 mg		ANOVA
		Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	P value
Baseline	5TSS	8.80	0.26	8.75	0.27	8.10	0.23	8.39	0.24	NS
	4NTSS	7.67	0.21	7.38	0.22	7.07	0.20	7.23	0.18	NS
2 weeks	5TSS	5.74	0.46	4.18**	0.34	3.04**	0.28	3.38**	0.32	<0.001
	4NTSS	5.10	0.39	3.63**	0.29	2.75**	0.25	2.92**	0.27	<0.001
4 weeks	5TSS	5.57	0.42	3.61**	0.41	2.82**	0.28	3.85**	0.38	<0.001
	4NTSS	5.00	0.36	3.14**	0.36	2.54**	0.26	3.23**	0.30	<0.001
change from baseline (4 weeks)	5TSS	−3.23	0.44	−5.20**	0.46	−5.21**	0.32	−4.55*	0.37	0.001
	4NTSS	−2.67	0.37	−4.28**	0.41	−4.48**	0.29	−4.00**	0.32	0.001
% change from baseline	5TSS	−34.76	5.09	−57.93**	4.79	−64.34**	3.55	−54.75**	4.17	<0.001
	4NTSS	−33.17	5.07	−55.92**	5.13	−63.51**	3.70	−54.95**	4.02	<0.001

Notes:

* P<0.05 vs placebo;

** P<0.01 vs placebo.

Abbreviation: NS, not significant.

Table 3 Summary of evening (evening reflective) total symptoms score (5TSS) assessments and nasal total symptoms score (4NTSS) (ITT population)

		Placebo		Rupatadine 10 mg		Rupatadine 20 mg		Cetirizine 10 mg		ANOVA
		Mean	SEM	Mean	SEM	Mean	SEM	Mean	SEM	P value
Baseline	5TSS	8.80	0.26	8.75	0.27	8.10	0.23	8.39	0.24	NS
	4NTSS	7.67	0.21	7.38	0.22	7.07	0.20	7.23	0.18	NS
2 weeks	5TSS	5.10	0.45	3.74**	0.32	3.01**	0.27	3.14**	0.31	< 0.001
	4NTSS	4.53	0.38	3.29**	0.29	2.68**	0.23	2.68**	0.27	< 0.001
4 weeks	5TSS	5.47	0.42	3.41**	0.37	2.76**	0.28	3.35**	0.36	< 0.001
	4NTSS	4.89	0.37	2.98**	0.32	2.50**	0.25	2.82**	0.29	< 0.001
change from baseline (4 weeks)	5TSS	−3.33	0.45	−5.41**	0.43	−5.34**	0.35	−5.05**	0.35	<0.001
	4NTSS	−2.79	0.39	−4.44**	0.37	−4.57**	0.31	−4.41**	0.31	<0.001
% change from baseline	5TSS	−35.98	5.14	−60.11**	4.35	−64.56**	3.61	−60.62**	3.88	<0.001
	4NTSS	−34.65	5.22	−58.20**	4.49	−63.65**	3.66	−61.05**	3.76	<0.001

Notes:

* P<0.05 vs placebo;

** P<0.01 vs placebo.

Abbreviation: NS, not significant.

On page 33, Figure 3 was incorrect. The corrected figure is shown below.

Figure 3 Evolution of total symptoms score (5TSS): A) morning evaluation for the 5TSS scores during study period; B) evening evaluation for the 5TSS scores during the study period